Stephen A Firkins

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Arterial Hypertension

Emergency Department

Oxidative Stress

Top Venues

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics 59 (9) (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics 59 (9) (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics 59 (9) (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics 59 (9) (2024)